<DOC>
	<DOC>NCT01720160</DOC>
	<brief_summary>The purpose of this research study is to show whether the Neo system is safe and works in people with heart failure. The study is currently in long-term follow up.</brief_summary>
	<brief_title>Barostim HOPE4HF (Hope for Heart Failure) Study</brief_title>
	<detailed_description>A prospective, randomized study describing the safety and efficacy of the Neo system in approximately 60 heart failure subjects with a left ventricular ejection fraction equal or less than 35 percent.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age 21 years or above. On optimal, guidelinedirected (per the American Heart Association/American College of Cardiology guidelines), stable, heartfailure medications and dose for at least 4 weeks prior to screening. Known or suspected baroreflex failure or autonomic neuropathy. Myocardial infarction, unstable angina, syncope, cerebral vascular accident, sudden cardiac death (SCD), or received defibrillation therapy within 3 months. Heart failure secondary to a reversible cause or treatable condition.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>